News Medical on MSN13 小时
Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...
PharmiWeb7 小时
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...